[ back to News ]

Concert Pharmaceuticals to Present at the Oppenheimer 21st Annual Healthcare Conference on November 3, 2010

October 27 , 2010

Lexington, MA –- Concert Pharmaceuticals, Inc. announced today that Roger Tung, Ph.D., President and Chief Executive Officer of Concert, will present at the Oppenheimer 21st Annual Healthcare Conference on Wednesday, November 3, 2010 at 2:25 p.m. ET. The conference will be held November 2-3, 2010 at the Waldorf=Astoria in New York City.

About Concert

Concert Pharmaceuticals is a clinical stage biotechnology company focused on applying the company’s DCE Platform™ to create novel and differentiated small molecule drugs containing deuterium. Concert’s approach leverages the known activity and safety of existing drugs to reduce the time, risk and expense of drug research and development. The Company has a broad research pipeline encompassing many therapeutic areas including infectious disease and renal disease, among others. In 2009, Concert entered into a potential $1 billion strategic alliance with GlaxoSmithKline to develop and commercialize certain deuterium-containing medicines. Founded in 2006, Concert has raised more than $110 million of venture and institutional capital. For more information on Concert Pharmaceuticals, please visit www.concertpharma.com.

Concert Pharmaceuticals, the CoNCERT logo and DCE Platform are trademarks of Concert Pharmaceuticals, Inc.

[ back to top ]